Claimed by the founder of the CAMCON group, Prof. Wladyslaw Wygnanski, as the first new medical gas delivery device for oxygen in 100 years, the technology enables an “unprecedented” rate of oxygen delivery, an advantage who could see Camcon Medical’s technology deployed for Covid-19 patients.

The patented BAT valve technology acts as a fast and precise on / off switching device of liquid or gas, requiring a very short electrical pulse to toggle a valve between “open” and “close”.

As BAT technology has been used in the oil, gas and automotive industry, Camcon Medical has modified the valve for use as a medical device for delivering oxygen, reducing the lack of oxygen in acute respiratory failure. and chronic.

Commenting on the use of BAT in the oxygen supply, Danny Chapchal, President of Camcon Medical, explained: “It uses advanced engineering to deliver precise amounts of medicinal gases, such as oxygen, at the optimum time. each the best areas of the lung for oxygen absorption.

“Its goal as a fully automated delivery system is to reduce the burden on clinicians in intensive care units (ICUs) and, in the future, allow patients to use the device at home. ”

With the intention of “radically changing” the way oxygen is delivered to help patients with respiratory failure, Camcon Medical views the device as a solution to help patients with respiratory failure due to respiratory problems. SARS-CoV-2 infection, pneumonia and COPD.

How does the technology work?

The device, known as BiMOD, features dual valves developed from the company’s original single valve prototype, Intelligent Medical Oxygen Delivery (iMOD), Camcon Medical’s first medical device to use the BAT valve.

BiMOD provides oxygen as well as nitric oxide, a potent pulmonary artery vasodilator. This simultaneous gas distribution reaches the lungs and allows for improved blood circulation and greater oxygen uptake.

Camcon Medical Clinical and Scientific Advisor Prof Tim Higenbottam commented on how the technology works, saying that the device’s key physiological step is made possible by the precise timing and dose of the two gases.

He continued, “At Camcon Medical, we believe we can reduce the high mortality resulting from diseases like Covid-19, pneumonia and other forms of acute respiratory distress syndrome (ARDS) by delaying and avoiding mechanical ventilation. invasive of these patients. ”

“Our goal is to improve gas exchange in the ‘injured’ lung using both gases.”

Advantages of BiMOD over existing IMV treatment

BiMOD’s automatic gas delivery and its ability to sense and monitor the patient’s oxygen demand can delay or prevent a patient’s need for invasive mechanical ventilation (IMV), according to Higenbottam.

At the start of the Covid-19 pandemic, IMV was the treatment of choice for patients with respiratory failure. The inherently invasive nature of the procedure means that patients’ lungs are forced to open rather than target areas that are still functional.

This requires the patient to be sedated and monitored by hospital staff at all times and, in part due to the additional damage to lung tissue, results in a 40% death rate.

Other methods of delivering oxygen, such as nasal cannula (HNFO) or continuous positive airway pressure (CPAP) fail to avoid the need for mechanical ventilation according to NICE results, with CPAP being able to cause additional lung damage.

Higenbottam explained why the BiMOD device also reduces oxygen waste and can reduce the company’s carbon footprint: “About 2/3 of the oxygen is wasted for patients receiving oxygen. ”

“If you consider the high flow rate of 75 liters per minute for some patients receiving constant oxygen, that works out to about 50 liters per minute wasted, per patient.”

“It’s bad for the NHS balance sheet and bad for the environment given the carbon footprint of producing medical grade oxygen,” he said.

He added that the precise and efficient nature of BiMOD’s oxygen delivery system could also reduce pressure on industries stretched to breaking point due to supply chain complications induced by Covid or Brexit.

“4.5 million patients worldwide use long-term oxygen therapy and 15,000 patients in UK hospitals receive oxygen therapy every day. It’s a huge footprint, ”he concluded.

Alternative applications of BiMOD technology

With potential for a wide range of industrial applications, Wygnanski explained that the device’s technology features lend themselves to both the gas and cryogenic industry.

Commenting on the BAT valves, he said: “The conditional unstable option can be active above or below a certain physical limit (temperature, pressure, etc.) used a protection system with automatic activation in case of power failure or dead battery.

“A zero current multi-valve matrix option represents any complex gas or liquid distribution network, which can remain unchanged in the event of a power failure or which can disconnect only preselected sections. ”

With the resumption of secure distribution after the power grid is restored, the technology could be used to control any large gas or liquid distribution network.

The plan ahead …

Chapchal explained that the technology will be a priority to treat pneumonia induced by Covid-19 and other forms of ARDS, before moving on to the outpatient investigation of chronic respiratory failure, such as patients living with the disease. COPD who need a constant supply of home oxygen.

He added, “Essentially, we want to help people with chronic lung disease live fuller lives where they can move around and participate in more activities rather than being confined to a predominantly lifestyle. sedentary. ”

“The main advantages of the technology are its ability to be automated and meet the exact oxygen needs of the patient, acting like the clinician by choosing precise timing, precise delivery rates and precise doses.”

This emphasis on precision could help improve patient outcomes and reduce the workload of clinical staff in hospitals.

Camcon Medical sees BiMOD technology as an opportunity to use machine learning and artificial intelligence (AI) for gas delivery, as well as to help merge the gas production and distribution industries with the gas industry. health to alleviate respiratory failure caused by Covid-19 and other medical conditions.

In conclusion, the team added, “The BiMOD can learn certain daily routines from its owner or patient to predict gas supply in the most efficient way, but this would require a comprehensive research program in cooperation with main medical centers. ”

Provided it finds suitable investors, the company aims to increase manufacturing and be ready for mass production within two years.

Previous

Folklore and dreams woven into magic on canvas

Next

Military Platform Electro-Optics Market Size To Reach US $ 5.2 Billion In 2027, According To Stratview Research

Check Also